Skip to main content

Drug Interactions between nebivolol / valsartan and thallous chloride, tl-201

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

nebivolol thallous chloride Tl-201

Applies to: nebivolol / valsartan and thallous chloride, tl-201

MONITOR: Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201. Use of these drugs with thallous chloride TI-201 during imaging studies may result in a decrease in the number and size of perfusion defects, the appearance of false myocardial defects, and a decrease in myocardial localization and an increase in liver localization.

MANAGEMENT: Clinicians should be aware of possible diagnostic interference by these drugs.

References (3)
  1. Cerner Multum, Inc. "Australian Product Information."
  2. (2022) "Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201)." GE Healthcare
  3. Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy (2015) Drug - Radiopharmaceutical Interactions. http://nuclearpharmacy.uams.edu/nicki.html#tl

Drug and food interactions

Moderate

valsartan food

Applies to: nebivolol / valsartan

GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.

MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.

References (2)
  1. (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
  2. (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer